Myocardial protection by erythropoietin during resuscitation from ventricular fibrillation

American Journal of Therapeutics

Volumn 14, Issue 4, 2007, Pages 361-368

  Singh, Dinesh ^a   Kolarova, Julieta D ^b   Wang, Sufen ^b   Ayoub, Iyad M ^b   Gazmuri, Raúl J ^b,c  

^a Advocate Lutheran General Children's Hospital   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary resuscitation; Erythropoietin; Ischemia; Reperfusion; Ventricular fibrillation

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; COMPRESSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DEFIBRILLATION; ELECTROSTIMULATION; HEART ARREST; HEART INDEX; HEART MUSCLE PERFUSION; HEART PROTECTION; HEART RIGHT ATRIUM; HEART STROKE VOLUME; HEART VENTRICLE FIBRILLATION; LUNG VENTILATION; NONHUMAN; PRIORITY JOURNAL; RAT; RESUSCITATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CARDIOPULMONARY RESUSCITATION; ELECTRIC COUNTERSHOCK; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FIBRILLATION;

EID: 34547681401     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pap.0000249957.35673.f0     Document Type: Article

References (45)

1. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1-14.
2. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79-85.
3. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
4. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612-11617.
5. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
6. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990-994.
7. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation. 2004;109:2050-2053.
8. Lipsic E, van der MP, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
9. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279: 20655-20662.
10. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18:1031-1033.
11. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406-1412.
12. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97: 10526-10531.
13. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98: 4044-4049.
14. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci. 2002;22: 10291-10301.
15. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ. 2004;11 (Suppl 1):S37-44.
16. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99:2258-2263.
17. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99:10659-10664.
18. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348-355.
19. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004;22:63-69.
20. Buemi M, Vaccaro M, Sturiale A, et al. Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps. Acta Derm Venereol. 2002;82:411-417.
21. Gazmuri RJ, Weil MH, Bisera J, et al. Myocardial dysfunction after successful resuscitation from cardiac arrest. Crit Care Med. 1996;24:992-1000.
22. Kern KB, Hilwig RW, Rhee KH, et al. Myocardial dysfunction after resuscitation from cardiac arrest: An example of global myocardial stunning. J Am Coll Cardiol. 1996;28:232-240.
23. Klouche K, Weil MH, Sun S, et al. Evolution of the stone heart after prolonged cardiac arrest. Chest. 2002;122: 1006-1011.
24. Ayoub IM, Kolarova JD, Yi Z, et al. Sodium-hydrogen exchange inhibition during ventricular fibrillation: Beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitability. Circulation. 2003;107:1804-1809.
25. Kolarova JD, Ayoub IM, Gazmuri RJ. Cariporide enables hemodynamically more effective chest compression by leftward shift of its flow-depth relationship. Am J Physiol Heart Circ Physiol. 2005;288:H2904-H2911.
26. von Planta I, Weil MH, von Planta M, et al. Cardiopulmonary resuscitation in the rat. J Appl Physiol. 1988;65: 2641-2647.
27. Gazmuri RJ, Ayoub IM, Hoffner E, et al. Successful ventricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation. 2001;104:234-239.
28. Kolarova J, Yi Z, Ayoub IM, et al. Cariporide potentiates the effects of epinephrine and vasopressin by nonvascular mechanisms during closed-chest resuscitation. Chest. 2005;127:1327-1334.
29. 2000 Report of the AVMA Panel on Euthanasia. J Am Vet Med Assoc. 2001;218:669-696.
30. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med. 1989;110:108-114.
31. Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet. 1989;1:425-427.
32. Karmazyn M. The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Ann NY Acad Sci. 1999;874:326-334.
33. Gazmuri RJ, Ayoub IM, Kolarova JD, et al. Myocardial protection during ventricular fibrillation by inhibition of the sodium-hydrogen exchanger isoform-1. Crit Care Med. 2002;30:S166-S171.
34. Rafiee P, Shi Y, Su J, et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol. 2005;100:187-197.
35. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol. 2005;42:233-241.
36. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657.
37. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460.
38. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
39. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2005;15:69-75.
40. Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549.
41. Liu H, Zhang HY, Zhu X, et al. Preconditioning blocks cardiocyte apoptosis: role of K(ATP) channels and PKC-epsilon. Am J Physiol Heart Circ Physiol. 2002;282: H1380-H1386.
42. Holmuhamedov EL, Jovanovic S, Dzeja PP, et al. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol. 1998;275: H1567-H1576.
43. Shi Y, Rafiee P, Su J, et al. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol. 2004;99:173-182.
44. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther. 2005;19:33-40.
45. Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can J Anaesth. 2002;49:777-791.